SB
Shivprakash Bhubneshwar Mehta
About Shivprakash Bhubneshwar Mehta
Shivprakash Bhubneshwar Mehta has 4 years in corporate governance. Holds Designated Partner role. Currently with 3 companies, including Aasthajin Global Ventures Llp and Cadenza Healthcare Llp. Formerly with 1 company, such as Sinhagad Speciality Hospital Llp. Engaged in General Business, Healthcare. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Aasthajin Global Ventures Llp
ACQ-4123
|
Designated Partner | 15 Dec 2025 | 2025 | Active |
Cadenza Healthcare Llp
ACJ-1809
|
Designated Partner | 28 Aug 2024 | 2024 | Active |
Surgistar Healthcare Llp
ACH-7978
|
Designated Partner | 16 Jun 2024 | 2024 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Sinhagad Speciality Hospital Llp
ABA-3014
|
Partner | 20 Jan 2022 | 2022 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Shivprakash Bhubneshwar Mehta
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shivprakash Bhubneshwar Mehta
Shivprakash Bhubneshwar Mehta has 4 years in corporate governance. Holds Designated Partner role. Currently with 3 companies, including Aasthajin Global Ventures Llp and Cadenza Healthcare Llp. Formerly with 1 company, such as Sinhagad Speciality Hospital Llp. Engaged in General Business, Healthcare. Contributes to corporate operations.
Shivprakash Bhubneshwar Mehta is associated with 3 companies as Designated Partner.
Shivprakash Bhubneshwar Mehta has expertise in General Business, Healthcare.
Shivprakash Bhubneshwar Mehta has 4 years in corporate governance.